Spontaneous Pneumothoraces and Hemothoraces in Sarcomas

Ezzeddine, Fatima; Jalal, Shadia I.

doi:10.7759/cureus.1905

Cited by 4 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Soft tissue sarcomas metastasize with sizeable frequency, and in nearly one-fourth of patients, the disease metastasizes to the lungs, specifically [ 19 ]. With regard to secondary spontaneous pneumothorax as a further complication, several studies have been documented over the years [ 3 – 5 , 7 , 8 ]; recently, however, the incidence of SSP increased with the introduction of pazopanib for patients with sarcoma metastatic to the lungs [ 9 , 10 , 14 , 20 – 23 ]. If there is such an association, this would be problematic because pazopanib is an attractive therapeutic option, given data showing improved prognosis in advanced disease [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study

et al. 2018

View full text Add to dashboard Cite

BackgroundThe tyrosine kinase inhibitor pazopanib is used for treatment of sarcoma. Recent studies have suggested that the use of pazopanib may lead to the development of pneumothorax, an unexpected adverse effect in patients with sarcoma metastatic to the chest.MethodsWe conducted a retrospective case control study of patients with sarcoma with metastases to the chest with pneumothorax (cases) and without pneumothorax (controls). The control population was selected from tumor registry in a 1:4 (cases to controls) ratio. The primary outcome of interest was the association between pazopanib and pneumothorax risk in patients with sarcoma metastatic to the chest. Secondary objective was to evaluate risk factors for pneumothorax.ResultsWe identified 41 cases and 164 controls. Using purposeful selection method the odds of developing pneumothorax while being on pazopanib was not significant in univariate (p = .06) and multivariable analysis (p = .342). On univariate analysis risk factors of pneumothorax in patients with sarcoma were age, male sex, African American race, the presence of cavitary lung nodules/masses, and the presence of pleural-based nodules/masses. On multivariate analysis, only the presence of cavitary lung nodules/masses (P < .001) and the presence of pleural-based nodules/masses (P < .001) remained as risk factors for developing pneumothorax.ConclusionPazopanib does not increase the risk of pneumothorax in patients with sarcoma and evidence of metastatic disease to the chest. Presence of cavitary lung nodules/masses and the presence of pleural-based nodules/masses were found to be risk factors for pneumothorax.

show abstract

Section: Discussionmentioning

confidence: 99%

Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The ongoing discussion about the effectiveness and safety of standard PCNL versus mini-PCNL for the management of kidney stones persists, particularly for stones larger than 2 cm [5][6][7][8]. While standard PCNL typically employs larger tract sizes (24F-30F) compared to mini-PCNL (14F-22F), the latter is not meant as a replacement for the standard PCNL technique but rather to compete with other modalities such as ECRIS, ESWL, and RIRS [9].…”

Section: Discussionmentioning

confidence: 99%

Comparative Analysis of Standard Percutaneous Nephrolithotomy (PCNL) and Mini-Percutaneous Nephrolithotomy (Mini-PCNL) for Renal Stones Larger Than 2 cm at a Rural Hospital: A Study Protocol

Hatwar,

Dhale,

Dharamshi

et al. 2024

Cureus

View full text Add to dashboard Cite

BackgroundPercutaneous nephrolithotomy (PCNL) is considered a standard treatment option for large-size renal stones but is associated with drawbacks such as bleeding and prolonged recovery. Mini-PCNL offers a less invasive alternative, but its efficacy compared to standard PCNL for renal stones larger than 2 cm remains under debate. This study aims to compare the efficacy and safety of standard PCNL versus mini-PCNL for renal stone sizes more than 2 cm. MethodsThis single-centre prospective interventional study will be conducted at Acharya Vinoba Bhave Rural Hospital (AVBRH). The study will include patients 18 to 70 years of age undergoing unilateral PCNL for renal calculi. Patients with renal stones larger than 2 cm will be enrolled. Data on stone-free rate (SFR), operative duration, hospital stay time, surgical site infection, haemoglobin (Hb) drop, need for blood transfusion, and post-surgery fever will be collected and compared between the two procedures. Statistical analysis of data will be performed using descriptive and analytical statistics. ResultsThe study aims to enrol a total of 32 patients. Data analysis will be done using IBM SPSS Statistics for Windows, Version 24 (Released 2016; IBM Corp., Armonk, New York). ConclusionThis study will provide valuable insights into the comparative outcome in terms of efficacy and safety of standard PCNL and mini-PCNL for kidney stones larger than 2 cm.

show abstract

“…Além da agressividade, o tumor pode causar metástases em até 60% dos casos 9 , sendo o pulmão um dos principais focos, podendo ocasionar dispneia, dor torácica e choque nos casos de hemotórax maciço 11 . Em restritas ocasiões a crise dispneica pode decorrer de um pneumotórax agudo paraneoplásico, tendo os angiosarcomas e sarcomas osteogênicos como diagnósticos diferenciais 12 .…”

Section: Discussionunclassified

“…A própria quimioterapia pode predispor ao pneumotórax, como relatado pelo estudo do Japanese Musculoskeletal Oncology Group (JMOG) com 32 portadores de sarcomas de partes moles metastáticos refratários à quimioterapia inicial e tratados com pazopanibe, cujo manejo e as condições são semelhantes às do paciente supracitado. Dentre eles, 9,4% desenvolveram pneumotórax após a terapêutica 12 .…”

Section: Discussionunclassified

Hemotórax paraneoplásico metastático de schwannoma maligno: um relato de caso

Gonzatti¹,

Preti²,

Franco³

et al. 2022

Relatos Casos Cir.

View full text Add to dashboard Cite

Introdução: O sarcoma é uma neoplasia mesenquimal que pode cursar com metástase, principalmente pulmonar. Uma minoria dos casos metastáticos pode sangrar e causar hemotórax, principalmente o angiosarcoma ou, menos provável, o tumor maligno da bainha do nervo periférico (TMBNP). Relato do caso: Homem, 63 anos, portador de TMBNP da coxa tratado com cirurgia e adjuvância com quimioterapia e radioterapia. Quatro meses após o tratamento da recidiva, apresentou dor ventilatório dependente e síncope, com evidência de metástases e derrame pleural volumoso à direita na tomografia. À videotoracoscopia foi diagnosticado hemotórax maciço e duas metástases pulmonares rotas, ativamente sangrantes que foram ressecadas. Após alta, iniciou pazopanibe, mas evoluiu com quadro de caquexia neoplásica e óbito. Conclusão: O hemotórax maciço por metástases de sarcomas é raro, mas em pacientes oncológicos com dispneia aguda ou dor pleurítica deve ser diagnóstico diferencial para a correta conduta. Palavras-chave: Sarcoma. Hemotórax. Metástase Neoplásica.

show abstract

Spontaneous Pneumothoraces and Hemothoraces in Sarcomas

Cited by 4 publications

References 7 publications

Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study

Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study

Comparative Analysis of Standard Percutaneous Nephrolithotomy (PCNL) and Mini-Percutaneous Nephrolithotomy (Mini-PCNL) for Renal Stones Larger Than 2 cm at a Rural Hospital: A Study Protocol

Hemotórax paraneoplásico metastático de schwannoma maligno: um relato de caso

Contact Info

Product

Resources

About